Belite Bio, Inc. (BLTE) saw its shares soar 5.27% during intraday trading on Wednesday, as investors reacted to the company's latest corporate update and financial results.

The clinical-stage biopharmaceutical company announced it has initiated a rolling submission of a New Drug Application (NDA) to the U.S. FDA for its lead candidate, tinlarebant, for the treatment of Stargardt disease type 1. The submission is expected to be completed in the second quarter of 2026. Furthermore, Belite Bio reported that commercialization preparation for the potential treatment is underway, with the hiring of all key commercial leadership positions already completed. The company also maintains a strong financial position, with cash, cash equivalents, and U.S. treasury holdings totaling $798.6 million as of March 31, 2026.

Despite reporting a wider net loss for the first quarter, Wall Street analysts remain bullish on the stock. According to recent reports, the current average analyst rating is "buy" with eight "strong buy" or "buy" recommendations and no "sell" ratings. The median 12-month price target is $200.50, representing a significant potential upside from recent trading levels, which appears to be driving positive investor sentiment.